2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2099

Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong
Abstract Number: 1442

Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis
Abstract Number: 1437

Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease
Abstract Number: 2107

Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database
Abstract Number: 688

Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort
Abstract Number: 1825

Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis
Abstract Number: 1447

Comparison of Ultra High‐resolution Ultrasound (UHFUS) of Labial Salivary Glands and Conventional Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome Assessment
Abstract Number: 2688

Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort
Abstract Number: 669

Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria
Abstract Number: 2132

Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus
Abstract Number: 642

Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus
Abstract Number: 2895

Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis
Abstract Number: 787

Complement Protein Levels Reflect Disease Activity in Juvenile Idiopathic Arthritis
Abstract Number: 323

Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients
Abstract Number: 2146

Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].